查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046897

慢性疼痛治療​​市場－全球產業規模、佔有率、趨勢、機會與預測：按適應症、產品類型、分銷管道、地區和競爭格局分類，2021-2031年

Chronic Pain Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Product Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球慢性疼痛治療​​市場預計將從 2025 年的 862.3 億美元大幅成長至 2031 年的 1,365.3 億美元，複合年成長率為 7.96%。

該市場涵蓋了旨在控制持續三個月以上疼痛的各種解決方案，包括藥品、醫療設備和各種治療方法。推動這一市場成長的關鍵因素包括全球人口老化以及關節炎、神經病變和癌症等慢性疾病的日益普遍。國際疼痛研究協會 (IASP) 的報告凸顯了對這些療法的巨大需求。該協會在 2024 年發布的報告指出，屆時全球將有超過 20% 的人口遭受慢性疼痛的困擾，因此迫切需要有效且易於獲得的治療方法來緩解這一普遍存在的健康危機。

市場概覽
預測期 2027-2031
市場規模：2025年 862.3億美元
市場規模：2031年 1365.3億美元
複合年成長率：2026-2031年 7.96%
成長最快的細分市場 神經性疼痛
最大的市場 北美洲

儘管鴉片類鎮痛藥市場具有巨大的成長潛力，但仍面臨許多挑戰。其中一個主要因素是，由於全球對濫用和成癮的擔憂，鴉片類止痛藥受到嚴格的監管。監管力度的增加導致處方指南更加嚴格，使得醫療專業人員不願開立此類藥物，也阻礙了患者獲得現有治療方法。因此，製藥公司在研發非成癮性替代藥物的過程中，面臨克服複雜監管障礙的巨大挑戰。這種情況不僅使研發進度複雜化，也限制了慢性疼痛治療​​領域的快速發展。

市場促進因素

市場擴張的主要驅動力是慢性病盛行率的不斷上升，這主要是由於全球人口老化和文明病的增加。隨著老年人口的成長，骨關節炎和糖尿病神經病變等退化性疾病的發生率也在上升，確保了對治療方案的持續需求。美國疾病管制與預防中心 (CDC) 的數據也印證了患者群體的擴大。 CDC 在 2024 年 11 月發布的報告顯示，2023 年美國成年人中有 24.3% 患有慢性疼痛。如此高的盛行率也帶來了巨大的經濟負擔；根據國際藥物經濟與結果研究協會 (ISPOR) 估計，2024 年美國慢性疼痛管理的費用將達到每年 7,250 億美元。這反過來又推動了有效治療方法的普及應用。

同時，神經刺激和各種疼痛管理設備的科技進步正在改變市場格局，提供先進的非鴉片類治療方法。各公司正積極推出新一代脊髓刺激（SCS）系統，旨在提供精準、個人化的疼痛緩解，同時最大限度地減少副作用。這些創新解決方案正迅速獲得醫療專業人士的支持，尤其是在鴉片類藥物處方監管日益嚴格的背景下。近期行業統計數據表明，這些技術發展帶來了顯著的商業性影響。 2024年10月，波士頓科學公司報告稱，其神經調控部門2024年第三季淨銷售額達2.68億美元，年增17.0%。這一強勁的業績凸顯了市場對基於醫療設備的治療方法在治療頑固性疼痛方面日益成長的需求。

市場挑戰

全球慢性疼痛治療​​市場面臨許多挑戰，主要原因在於鴉片類止痛藥法規結構的嚴格性。這種日益嚴格的審查源於全球對濫用和成癮問題的擔憂，並已從根本上改變了疼痛管理的處方方式。如今，醫療專業人員在更嚴格的指導方針下開展工作，這些方針不鼓勵使用傳統的鴉片類藥物療法，導致即使對於合法的慢性疾病，醫生在開立此類治療方法時也猶豫不決。此類監管壓力直接阻礙了患者獲得治療，並有效地縮小了現有藥物療法的市場規模。因此，市場面臨瓶頸，整體收入成長停滯不前，因為鴉片類藥物使用量的下降尚未被非鴉片類替代藥物的普及所抵消。

這些限制的嚴重性已得到近期行業數據的有力佐證，數據顯示此類藥物的供應量急劇下降。例如，美國醫學會（AMA）在2024年報告稱，全美鴉片類藥物處方量將比2012年下降近52%。這一顯著下降表明，受嚴格監管的止痛藥正逐漸縮小其市場佔有率。製藥公司被迫緊急開發新的治療方案以填補這一空白，同時還要應對複雜的合規程序，這不可避免地會延緩新產品的上市，並限制更廣泛治療市場的快速擴張。

市場趨勢

市場關鍵趨勢之一是非鴉片類藥物療法的快速普及。這主要得益於製藥公司成功克服傳統障礙，推出創新且無成癮性的長期疾病治療方法。這項進展透過引入鈉通道抑制劑和舌下製劑等新型藥物，有效避免了傳統鴉片類藥物帶來的風險，從而滿足了人們對更安全止痛的迫切需求。美國FDA於2025年8月核准Tonmya（TNX-102 SL）上市，便是這項變革性變化的典型例證（HCPLive於2026年1月報道）。這是15年來首個獲準用於治療纖維肌痛的新藥，體現了製藥業致力於開發有效且無成癮性的藥物療法，並為數百萬遭受難治性慢性疼痛折磨的患者拓展治療選擇的戰略重點。

同時，數位療法與遠端患者監護的融合正在從根本上改變醫療保健的提供方式，使肌肉骨骼疼痛和慢性疼痛患者能夠在家中接受持續管理。這些先進的平台利用穿戴式感測器和人工智慧來指導物理治療、監測藥物依從性並即時客製化干涉措施，從而減少患者頻繁就診的需求。該領域領先創新者的強勁財務業績表明，這些數位解決方案具有商業性可行性並迅速普及，他們已有效地將這些虛擬護理模式商業化。根據 MobiHealthNews 2025 年 8 月報道，Hinge Health 在 2025 年第二季的銷售額為 1.391 億美元，年成長 55%。這種普及率的激增清楚地表明，醫療保健提供者和保險公司越來越認知到，數位方法是現代慢性疼痛治療​​方案中不可或缺且可擴展的組成部分。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球慢性疼痛治療​​市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（神經性疼痛、止痛注射、消融術）
    • 依產品類型（藥品、醫療設備）
    • 分銷管道（醫院/診所、門診部、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美慢性疼痛治療​​市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲慢性疼痛治療​​市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區慢性疼痛治療​​市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲慢性疼痛治療​​市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲慢性疼痛治療​​市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球慢性疼痛治療​​市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Pfizer Inc
  • Abbott Laboratories
  • Eli Lilly and Company
  • Novartis AG
  • Johnson & Johnson
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd
  • Baxter International
  • Merck & Co. Inc
  • Boston Scientific Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17451

The Global Chronic Pain Treatment Market is projected to expand significantly, rising from USD 86.23 Billion in 2025 to USD 136.53 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 7.96%. This market includes a range of solutions, from medications and medical devices to various therapies, all aimed at managing pain that lasts over three months. Key factors propelling this growth include a globally aging population and an increasing prevalence of chronic conditions like arthritis, neuropathy, and cancer. The immense demand for these treatments is highlighted by the International Association for the Study of Pain, which reported in 2024 that more than 20% of the world's population suffered from chronic pain, emphasizing the urgent need for effective and readily available therapeutic options to alleviate this widespread health crisis.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 86.23 Billion
Market Size 2031USD 136.53 Billion
CAGR 2026-20317.96%
Fastest Growing SegmentNeuropathic Pain
Largest MarketNorth America

Despite this growth potential, the market faces considerable obstacles, primarily due to strict regulations imposed on opioid analgesics, driven by global concerns about abuse and addiction. Increased oversight has resulted in more rigorous prescription guidelines, which in turn cause reluctance among healthcare providers and hinder patient access to established treatments. Consequently, manufacturers encounter significant challenges in navigating complex regulatory frameworks as they strive to develop non-addictive alternatives. This situation complicates development timelines and limits the swift expansion of the chronic pain treatment landscape.

Market Driver

A major catalyst for market expansion is the escalating prevalence of chronic health conditions, largely influenced by an aging global population and a rise in lifestyle-related disorders. The growing number of elderly individuals leads to a higher incidence of degenerative diseases, such as osteoarthritis and diabetic neuropathy, ensuring a continuous demand for therapeutic solutions. This expanding patient demographic is supported by data from the Centers for Disease Control and Prevention (CDC), which reported in November 2024 that 24.3% of U.S. adults experienced chronic pain in 2023. Such high incidence also imposes a substantial economic burden, estimated at $725 billion annually in the U.S. for chronic pain management in 2024, according to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), thereby encouraging the adoption of effective treatments.

Simultaneously, technological advancements in neurostimulation and various pain management devices are transforming the market by offering advanced non-opioid options. Companies are actively bringing to market next-generation spinal cord stimulation (SCS) systems, which are designed to provide precise and individualized pain relief while minimizing side effects. These innovative solutions are quickly gaining favor among healthcare professionals, especially as they contend with stricter opioid prescription regulations. The significant commercial impact of these technological developments is evident in recent industry figures, with Boston Scientific reporting in October 2024 that its Neuromodulation segment achieved $268 million in net sales, reflecting a 17.0% year-over-year growth in the third quarter of 2024. This strong performance underscores a growing preference for device-based interventions in addressing intractable pain.

Market Challenge

The Global Chronic Pain Treatment Market encounters significant hurdles primarily due to the strict regulatory framework surrounding opioid analgesics. This intensified oversight, stemming from worldwide concerns about abuse and addiction, has fundamentally reshaped how pain management prescriptions are issued. Healthcare providers now operate under more restrictive guidelines that discourage traditional opioid therapies, resulting in considerable reluctance to prescribe these treatments, even for valid chronic conditions. Such regulatory pressure directly impedes patient access and effectively shrinks the market for a substantial portion of existing pharmacotherapies. Consequently, the market faces a bottleneck where the reduction in opioid use is not yet balanced by the uptake of non-opioid alternatives, leading to stagnation in overall revenue growth.

The extent of these limitations is clearly demonstrated by recent industry data, which indicates a sharp decline in the availability of these medications. For instance, the American Medical Association reported in 2024 that opioid prescriptions nationwide had fallen by nearly 52% since 2012. This dramatic decrease illustrates how regulatory actions are actively diminishing the commercial presence of established pain treatments. In response, manufacturers are compelled to navigate intricate compliance procedures while urgently developing new therapeutic options to bridge this gap, a process that invariably slows the introduction of novel products and restricts the rapid expansion of the wider treatment market.

Market Trends

A significant market trend is the rapid embrace of non-opioid pharmacological therapies, driven by manufacturers' success in overcoming previous hurdles to introduce innovative, non-addictive treatments for long-term conditions. This development addresses the crucial demand for safer pain relief by introducing new drug classes, such as sodium channel inhibitors and sublingual formulations, which effectively circumvent the risks associated with conventional opioids. A prime example of this transformative shift is the regulatory approval of Tonmya (TNX-102 SL) by the U.S. FDA in August 2025, as reported by HCPLive in January 2026. This marked the first new pharmaceutical therapy for fibromyalgia in over 15 years, validating the industry's strategic focus on developing effective, non-habit-forming pharmacological options and thereby broadening the treatment landscape for millions suffering from intractable chronic pain.

Simultaneously, the integration of digital therapeutics and remote patient monitoring is fundamentally transforming healthcare delivery by offering continuous, home-based management for individuals with musculoskeletal and chronic pain. These advanced platforms utilize wearable sensors and artificial intelligence to guide physical therapy, monitor adherence, and customize interventions in real-time, consequently reducing the necessity for frequent in-person clinic visits. The commercial viability and swift adoption of these digital solutions are evident in the robust financial performance of leading innovators in this sector who are effectively monetizing these virtual care models. According to MobiHealthNews in August 2025, Hinge Health reported a 55% year-over-year revenue increase in the second quarter of 2025, reaching $139.1 million. This surge in adoption clearly demonstrates that healthcare providers and payers are increasingly recognizing digital modalities as vital, scalable elements of contemporary chronic pain treatment protocols.

Key Market Players

  • Pfizer Inc
  • Abbott Laboratories
  • Eli Lilly and Company
  • Novartis AG
  • Johnson & Johnson
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd
  • Baxter International
  • Merck & Co. Inc
  • Boston Scientific Corporation

Report Scope

In this report, the Global Chronic Pain Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Pain Treatment Market, By Indication

  • Neuropathic Pain
  • Analgesic Infusion
  • Ablation

Chronic Pain Treatment Market, By Product Type

  • Drugs
  • Devices

Chronic Pain Treatment Market, By Distribution Channel

  • Hospital & Clinics
  • Ambulatory Centers
  • Others

Chronic Pain Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Pain Treatment Market.

Available Customizations:

Global Chronic Pain Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Pain Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Neuropathic Pain, Analgesic Infusion, Ablation)
    • 5.2.2. By Product Type (Drugs, Devices)
    • 5.2.3. By Distribution Channel (Hospital & Clinics, Ambulatory Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Chronic Pain Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Product Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chronic Pain Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Product Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Chronic Pain Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Product Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Chronic Pain Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Product Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Chronic Pain Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Product Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chronic Pain Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Chronic Pain Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Chronic Pain Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Chronic Pain Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Product Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Chronic Pain Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Product Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Chronic Pain Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Product Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Chronic Pain Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Chronic Pain Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Chronic Pain Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Chronic Pain Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Chronic Pain Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Chronic Pain Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Product Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Chronic Pain Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Chronic Pain Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Chronic Pain Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Chronic Pain Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Product Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Chronic Pain Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Chronic Pain Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Chronic Pain Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Chronic Pain Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories
  • 15.3. Eli Lilly and Company
  • 15.4. Novartis AG
  • 15.5. Johnson & Johnson
  • 15.6. Sanofi SA
  • 15.7. Teva Pharmaceutical Industries Ltd
  • 15.8. Baxter International
  • 15.9. Merck & Co. Inc
  • 15.10. Boston Scientific Corporation

16. Strategic Recommendations

17. About Us & Disclaimer